Zepbound starts at 2.5 mg once weekly for four weeks, followed by 5 mg once weekly. Further increases happen in 2.5 mg steps after at least four weeks at the current dose, when the prescribing clinician determines that a change is appropriate. The maximum recommended dose is 15 mg once weekly. Reaching that maximum is not the goal for every person.
This guide explains the current U.S. label for adults, including the difference between a starting dose, an increase between doses, and a maintenance dose. It does not establish a personal schedule or apply to compounded tirzepatide. The Zepbound prescribing information was revised in August 2026.
Zepbound dosage chart: starting, increasing, and maintaining
Zepbound contains tirzepatide and is injected under the skin once a week. Its approved uses include weight reduction and long-term weight maintenance in eligible adults, and moderate to severe obstructive sleep apnea in adults with obesity. Those uses do not have identical maintenance-dose recommendations.
| Dose once weekly | Role in the labeled schedule | What to understand |
|---|---|---|
| 2.5 mg | Starting dose for four weeks | This is an initiation dose, not an approved maintenance dose. |
| 5 mg | The next dose after the initial four weeks | An approved maintenance option for weight management. |
| 7.5 mg | A possible step between 5 and 10 mg | Not listed as a recommended maintenance dose. |
| 10 mg | A possible maintenance dose | Listed for both weight management and sleep apnea. |
| 12.5 mg | A possible step between 10 and 15 mg | Not listed as a recommended maintenance dose. |
| 15 mg | The maximum recommended dose | Listed for both weight management and sleep apnea. |
After reaching 5 mg, an increase is not automatic simply because another month has passed. The label directs clinicians to consider treatment response and tolerance when choosing maintenance treatment. If someone does not tolerate a maintenance dose, the clinician may consider a lower maintenance dose. Source: Zepbound label, sections 2.1–2.2.
For a broader explanation of the ingredient, see our tirzepatide treatment questions guide.
Why increase Zepbound gradually?
The stepwise introduction helps reduce the risk of digestive adverse effects. Nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reflux can interfere with meals, fluid intake, and daily activities. Increasing too quickly can make the treatment harder to tolerate.
A dose increase is therefore a clinical decision with two parts: whether more treatment benefit is needed and whether the current treatment is tolerable. A person with persistent vomiting needs an assessment, even if their next calendar reminder says it is time to increase. A person doing well at a recommended maintenance dose may not need the next strength.
An appointment is more useful when you can describe appetite, meals, bowel habits, hydration, symptoms, and progress over several weeks. A single weigh-in, a social-media schedule, or a friend’s prescription does not answer those questions. Our guide to tirzepatide weight-loss plateaus explains how to review a trend without assuming the medicine has stopped working.
Is 5 mg enough, or should everyone reach 15 mg?
Five milligrams is one of the labeled maintenance options for weight management. Ten and 15 mg are the other listed options. The best fit depends on the person’s response, tolerance, medical history, and treatment goals.
The highest dose can be useful for some people, but “highest” does not mean “required.” Increasing treatment despite unacceptable symptoms can undermine eating, hydration, and the ability to continue care. Conversely, deciding to remain at an initiation dose indefinitely without discussing the plan is not the same as choosing a labeled maintenance option.
Ask your clinician what would count as a satisfactory response in your situation and what would trigger a review. That discussion should include function, relevant health measures, and whether the plan remains practical—not just the amount shown on a scale.
Does the dose differ for sleep apnea?
Yes. For moderate to severe obstructive sleep apnea in adults with obesity, the recommended maintenance dose is 10 or 15 mg once weekly. Treatment still starts at 2.5 mg weekly for four weeks and follows gradual escalation. A lower dose used for weight management should not be assumed to be the labeled sleep-apnea maintenance plan.
Zepbound’s approval for sleep apnea is product-specific. It does not mean that every compounded tirzepatide preparation has that approval. It also does not authorize stopping a CPAP or other prescribed sleep-apnea treatment. Your sleep clinician should review symptoms and objective results before making changes. Read more about tirzepatide and sleep apnea.
Milligrams, milliliters, pens, and vials are different
Milligrams describe the amount of medicine. Milliliters describe the liquid volume. A pen or vial is the device or container holding that medicine. Those details must be read together.
The current U.S. label includes single-dose pens and vials, as well as multidose vials and a single-patient-use KwikPen. Presentations can use different injection volumes. For example, the labeled single-dose presentations use 0.5 mL, while the listed multidose presentations provide 0.6 mL per dose. Do not transfer one device’s directions to another. Availability may differ from what the label lists.
The prescribing information specifically calls for training on the presentation you receive and new training when the presentation changes. Use the instructions supplied with the actual product. Never share a KwikPen, even after changing the needle. Do not try to extract leftover liquid, divide a dose using an online chart, or treat a device click as a universal unit of medicine. Source: Zepbound label, sections 2.4 and 3.
What if I miss a Zepbound dose?
The label says to take a missed dose as soon as possible within four days, or 96 hours, after the missed dose. If more than four days have passed, skip it and take the next dose on the usual day. Do not double doses to catch up.
The weekly day can be changed when necessary, provided there are at least three days, or 72 hours, between doses. These instructions address an occasional scheduling problem. After several missed weeks, a serious illness, or a gap caused by side effects, ask your clinician how to restart. The routine missed-dose rule is not a complete restart plan. Our missed tirzepatide dose guide covers the questions to bring.
Symptoms to discuss before another increase
Contact your prescriber if nausea, reflux, constipation, or diarrhea continues, interferes with eating, or makes work and daily activities difficult. Tell the team if you are eating very little, becoming unusually weak, or struggling to drink enough. Ask for advice before proceeding with a planned increase.
Seek urgent medical assessment for severe or persistent abdominal pain, repeated vomiting with inability to keep fluids down, or signs of significant dehydration. Stop the medication and seek immediate help for signs of a serious allergic reaction such as swelling of the lips or tongue, trouble breathing, or fainting. Severe abdominal pain that may extend to the back can be a sign of pancreatitis and needs prompt care. The Zepbound side-effects guide explains common symptoms and important warning signs in more detail.
People who take insulin or medicines such as sulfonylureas may need additional glucose monitoring or changes to those medicines because of hypoglycemia risk. Those changes should come from the prescribing team.
Other questions that belong in a dose review
Birth control: Tirzepatide can reduce the effectiveness of oral hormonal contraceptives. The label recommends switching to a nonoral method or adding a barrier method for four weeks after starting and for four weeks after each dose increase. Our tirzepatide and birth-control article explains why these checkpoints matter.
Pregnancy: Zepbound should be discontinued when pregnancy is recognized. Contact the prescribing clinician promptly to discuss care.
Surgery or sedation: Tell the anesthesia and procedural teams that you use Zepbound, including the dose, last injection, recent increases, and digestive symptoms. Do not invent your own stopping schedule.
Other GLP-1 medicines: The label does not recommend combining Zepbound with another tirzepatide product or a GLP-1 receptor agonist. Switching medicines requires a specific plan, not overlapping prescriptions.
Is morning or night better for a Zepbound injection?
The reviewed Zepbound label permits a once-weekly injection at any time of day, with or without meals. It does not establish a universal morning-versus-night weight-loss or side-effect advantage. Choose a workable time within the prescribed schedule and ask the care team about symptoms or administration difficulties. Changing the clock does not authorize a shorter interval, an extra injection or a dose increase. Missed-dose and day-change rules are separate questions, and tablets or another product may have different directions. Zepbound prescribing information.
Frequently asked questions
Can I increase after two weeks if I feel fine?
The labeled escalation interval is at least four weeks at the current dose. Feeling well after two injections is not a reason to shorten it on your own. Ask the clinician to review expectations if you are concerned about early progress.
Can I use this chart for a compounded vial?
No. A compounded vial has its own prescription, concentration, syringe instructions, and quality considerations. There is no universal conversion from a Zepbound dose to syringe units. FDA has reported serious errors with compounded GLP-1 dosing. Read FDA’s current guidance.
Is nausea a sign that the dose is working better?
Nausea is an adverse effect, not a treatment target. The goal is useful health benefit with acceptable tolerance. Severe symptoms should not be treated as proof of effective weight loss.
What should I bring to my next appointment?
Bring the exact product name and presentation, current dose, dates of recent injections, other medicines, symptom notes, and any relevant glucose readings. Include a realistic description of meals and fluid intake. Our first month on tirzepatide guide offers a practical tracking framework.
If you are comparing care options, review CoreAge Rx’s tirzepatide product information with a clinician. That product page is separate from this explanation of the FDA-approved Zepbound label; confirm the actual formulation and prescribing plan before starting.
Educational information for adults; individual treatment decisions require a qualified clinician. Sources checked September 26, 2026. Original AI-generated article illustrations depict fictional people and objects, not patient outcomes. Other editorial images are illustrative. Graphics summarize the cited sources.
